Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data
Summary
On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of additional SOL-1 clinical trial d...
Description
On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of additional SOL-1 clinical trial d...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source